Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Important Safety Information
Prescribing Information
Macrilen™ (macimorelin) 60 mg for oral solution logo

For the diagnosis of adult growth hormone deficiency.

Prescribing Information
Important Safety Information

NovoCare® is here for your patients every step of the way

NovoCare® is here for your patients every step of the way
Icon representing Macrilen™ (macimorelin) 60 mg co-pay assistance program

Macrilen™ Co-pay Savings Program

Macrilen™ Co-pay Savings Program

Eligible commercially insured patients may pay as little as $75.a,b  

To enroll your patients, contact NovoCare® at 1-888-668-6444. Or register online to file claims electronically.

Eligible commercially insured patients may pay as little as $75.a,b  

To enroll your patients, contact NovoCare® at 1-888-668-6444. Or register online to file claims electronically.

aWith an annual co-pay assistance of up to $4425.
bThis is a one-time use offer. Enrollment in the co-pay program is subject to eligibility criteria and terms and conditions, and the enrollment timeframe is based on calendar year. Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any Government Program. Patient must be enrolled in a commercial insurance plan. Coverage is limited to co-pay or co-insurance for Macrilen™ product only and does not include deductible amounts or other office visits, procedures, or administration costs. Novo Nordisk has the right to charge, alter, or revoke eligibility criteria and terms and conditions at any time.

NovoCare® logo

We designed NovoCare.com to provide a way for you to stay up to date with the status of your patients, communicate with your case managers, and submit NovoCare® paperwork online.

Macrilen™ (macimorelin) 60 mg umberella icon indicating product coverage resources available

Product coverage

  • Patient benefit verification and coverage information
  • Prior authorization and appeal resources
Macrilen™ (macimorelin) 60 mg reimbursement icon representing help available

Reimbursement

  • Coding information 
  • Resources for denials and appeals
Macrilen™ (macimorelin) 60 mg product distribution icon representing fulfillment

Product distribution

  • Information and authorized distributors 
  • Coordination of specialty pharmacy ordering and fulfillment

For more information or assistance, please call a NovoCare® representative at 1‑888‑668‑6444. Available Monday through Friday from 8:00 am to 8:00 pm ET.

Other questions?

Contact a Novo Nordisk representative for additional support.

Selected Important Safety Information for Macrilen™

Warnings and Precautions

  • QT Prolongation: Macrilen™ causes an increase of about 11 msec in the corrected QT (QTc) interval. QT prolongation can lead to development of torsade de pointes-type ventricular tachycardia with the risk increasing as the degree of prolongation increases. The concomitant use of Macrilen™ with drugs that are known to prolong the QT interval should be avoided

Indication and Limitation of Use

Macrilen™ (macimorelin) 60 mg for oral solution is indicated for the diagnosis of adult growth hormone deficiency (AGHD).

  • The safety and diagnostic performance of Macrilen™ have not been established for subjects with a body mass index (BMI) >40 kg/m2

Important Safety Information

Warnings and Precautions

  • QT Prolongation: Macrilen™ causes an increase of about 11 msec in the corrected QT (QTc) interval. QT prolongation can lead to development of torsade de pointes-type ventricular tachycardia with the risk increasing as the degree of prolongation increases. The concomitant use of Macrilen™ with drugs that are known to prolong the QT interval should be avoided
  • Potential for False Positive Test Results with Use of Strong CYP3A4 Inducers: Concomitant use of strong CYP3A4 inducers with Macrilen™ can decrease macimorelin plasma levels significantly and thereby lead to a false positive result. Strong CYP3A4 inducers should be discontinued and enough time should be given to allow washout of CYP3A4 inducers prior to test administration
  • Potential for False Negative Test Results in Recent Onset Hypothalamic Disease: Adult growth hormone (GH) deficiency caused by a hypothalamic lesion may not be detected early in the disease process. Macimorelin acts downstream from the hypothalamus and macimorelin stimulated release of stored GH reserves from the anterior pituitary could produce a false negative result early when the lesion involves the hypothalamus. Repeat testing may be warranted in this situation 

Adverse Reactions

  • The most common adverse reactions are dysgeusia, dizziness, headache, fatigue, nausea, hunger, diarrhea, upper respiratory tract infection, feeling hot, hyperhidrosis, nasopharyngitis, and sinus bradycardia

Please click here for Macrilen™ Prescribing Information.